Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael T Tetzlaff

Showing results (211-220 of 224) with videos related to

Pageof 23
Sort By:
Nature Medicine|October 27, 2018
Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanomaRodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
Science Translational Medicine|March 3, 2017
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistanceWhijae Roh, Pei-Ling Chen, Alexandre Reuben, et al.
The Lancet. Oncology|July 4, 2019
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma ConsortiumRodabe N Amaria, Alexander M Menzies, Elizabeth M Burton, et al.
Cancer Discovery|June 16, 2016
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint BlockadePei-Ling Chen, Whijae Roh, Alexandre Reuben, et al.
Nature|April 5, 2016
sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistanceAmanpreet Kaur, Marie R Webster, Katie Marchbank, et al.
Cancer Discovery|December 10, 2015
Loss of PTEN Promotes Resistance to T Cell-Mediated ImmunotherapyWeiyi Peng, Jie Qing Chen, Chengwen Liu, et al.
The Journal of Experimental Medicine|November 11, 2022
Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltrationYifan Zhou, Yusra B Medik, Bhakti Patel, et al.
Nature Communications|January 13, 2021
Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapyRajasekharan Somasundaram, Thomas Connelly, Robin Choi, et al.
NPJ Genomic Medicine|August 19, 2017
Genomic and immune heterogeneity are associated with differential responses to therapy in melanomaAlexandre Reuben, Christine N Spencer, Peter A Prieto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2022
Obesity Is Associated with Altered Tumor Metabolism in Metastatic MelanomaAndrew W Hahn, Ashley V Menk, Dayana B Rivadeneira, et al.
Pageof 23

Showing results (211-220 of 224) with videos related to

Sort By:
Pageof 23
Nature Medicine|October 27, 2018
Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanomaRodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
Science Translational Medicine|March 3, 2017
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistanceWhijae Roh, Pei-Ling Chen, Alexandre Reuben, et al.
The Lancet. Oncology|July 4, 2019
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma ConsortiumRodabe N Amaria, Alexander M Menzies, Elizabeth M Burton, et al.
Cancer Discovery|June 16, 2016
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint BlockadePei-Ling Chen, Whijae Roh, Alexandre Reuben, et al.
Nature|April 5, 2016
sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistanceAmanpreet Kaur, Marie R Webster, Katie Marchbank, et al.
Cancer Discovery|December 10, 2015
Loss of PTEN Promotes Resistance to T Cell-Mediated ImmunotherapyWeiyi Peng, Jie Qing Chen, Chengwen Liu, et al.
The Journal of Experimental Medicine|November 11, 2022
Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltrationYifan Zhou, Yusra B Medik, Bhakti Patel, et al.
Nature Communications|January 13, 2021
Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapyRajasekharan Somasundaram, Thomas Connelly, Robin Choi, et al.
NPJ Genomic Medicine|August 19, 2017
Genomic and immune heterogeneity are associated with differential responses to therapy in melanomaAlexandre Reuben, Christine N Spencer, Peter A Prieto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2022
Obesity Is Associated with Altered Tumor Metabolism in Metastatic MelanomaAndrew W Hahn, Ashley V Menk, Dayana B Rivadeneira, et al.
Pageof 23